Press Release
Category Added in a WPeMatico Campaign
-
Cision PR Newswire26 May 2026Applied Aerospace & Defense, Inc. Announces Launch of Initial Public Offering
HUNTSVILLE, Ala., May 26, 2026 /PRNewswire/ — Applied Aerospace & Defense, Inc., an advanced manufacturer of mission critical systems for…
Read More » -
Cision PR Newswire26 May 2026Cogent Communications Announces Definitive Agreement to Sell 10 Data Center Facilities
WASHINGTON, May 26, 2026 /PRNewswire/ — Cogent Communications Holdings, Inc. (“Cogent”) (NASDAQ: CCOI) today announced that its indirect wholly owned subsidiary,…
Read More » -
Cision PR Newswire26 May 2026Cogent Communications Announces Definitive Agreement to Sell 10 Data Center Facilities
WASHINGTON, May 26, 2026 /PRNewswire/ — Cogent Communications Holdings, Inc. (“Cogent”) (NASDAQ: CCOI) today announced that its indirect wholly owned subsidiary,…
Read More » -
Cision PR Newswire26 May 2026
Yiren Digital Comments on Recent Media Reports Concerning Affiliates of Its Controlling Shareholder
BEIJING, May 26, 2026 /PRNewswire/ — Yiren Digital Ltd. (NYSE: YRD) (“Yiren Digital” or the “Company”), a leading fintech company specializing…
Read More » -
Cision PR Newswire26 May 2026
Yiren Digital Comments on Recent Media Reports Concerning Affiliates of Its Controlling Shareholder
BEIJING, May 26, 2026 /PRNewswire/ — Yiren Digital Ltd. (NYSE: YRD) (“Yiren Digital” or the “Company”), a leading fintech company specializing…
Read More » -
Cision PR Newswire26 May 2026Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile
In a randomized, placebo-controlled, time-to-event trial in idiopathic generalized epilepsy (IGE), the median time to the second day with a…
Read More » -
Cision PR Newswire26 May 2026Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile
In a randomized, placebo-controlled, time-to-event trial in idiopathic generalized epilepsy (IGE), the median time to the second day with a…
Read More » -
Cision PR Newswire26 May 2026Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes
LONDON, May 26, 2026 /PRNewswire/ — Virax Biolabs Group Limited (NASDAQ: VRAX) (“Virax” or the “Company”) today reported positive early…
Read More » -
Cision PR Newswire26 May 2026Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes
LONDON, May 26, 2026 /PRNewswire/ — Virax Biolabs Group Limited (NASDAQ: VRAX) (“Virax” or the “Company”) today reported positive early…
Read More » -
Cision PR Newswire26 May 2026
Zepp Health Corporation to Report First Quarter 2026 Financial Results on June 8, 2026
Earnings Call Scheduled for 9:30 p.m. ET on June 8, 2026 MILPITAS, Calif., May 26, 2026 /PRNewswire/ — Zepp Health…
Read More »